The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study - PubMed (original) (raw)

Multicenter Study

The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study

Fatima Cody Stanford et al. Surg Obes Relat Dis. 2017 Mar.

Abstract

Background: Patients who undergo bariatric surgery often have inadequate weight loss or weight regain.

Objectives: We sought to discern the utility of weight loss pharmacotherapy as an adjunct to bariatric surgery in patients with inadequate weight loss or weight regain.

Setting: Two academic medical centers.

Methods: We completed a retrospective study to identify patients who had undergone bariatric surgery in the form of a Roux-en-Y gastric bypass (RYGB) or a sleeve gastrectomy from 2000-2014. From this cohort, we identified patients who were placed on weight loss pharmacotherapy postoperatively for inadequate weight loss or weight regain. We extracted key demographic data, medical history, and examined weight loss in response to surgery and after the initiation of weight loss pharmacotherapy.

Results: A total of 319 patients (RYGB = 258; sleeve gastrectomy = 61) met inclusion criteria for analysis. More than half (54%; n = 172) of all study patients lost≥5% (7.2 to 195.2 lbs) of their total weight with medications after surgery. There were several high responders with 30.3% of patients (n = 96) and 15% (n = 49) losing≥10% (16.7 to 195.2 lbs) and≥15% (25 to 195.2 lbs) of their total weight, respectively, Topiramate was the only medication that demonstrated a statistically significant response for weight loss with patients being twice as likely to lose at least 10% of their weight when placed on this medication (odds ratio = 1.9; P = .018). Regardless of the postoperative body mass index, patients who underwent RYGB were significantly more likely to lose≥5% of their total weight with the aid of weight loss medications.

Conclusions: Weight loss pharmacotherapy serves as a useful adjunct to bariatric surgery in patients with inadequate weight loss or weight regain.

Keywords: Bariatric surgery; Inadequate weight loss; Obesity; Obesity co-morbidities; Weight regain.

Copyright © 2017 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Disclosures

The authors have no commercial associations that might be a conflict of interest in relation to this article.

Figures

Fig. 1.

Fig. 1.

Demonstration of the utility of weight loss mediation after bariatric surgery in an RYGB patient. RYGB = Roux-en-Y gastric bypass; BMI = body mass index; TBWL = total body weight loss.

Comment in

References

    1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA 2014;311(8):806–14. - PMC - PubMed
    1. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and over-weight: A systematic review and meta-analysis. BMC Public Health 2009;9:88. - PMC - PubMed
    1. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: A systematic review and meta-analysis. JAMA 2004;292(14):1724–37. - PubMed
    1. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: An updated systematic review and meta-analysis, 2003–2012. JAMA Surg 2014;149(3):275–87. - PMC - PubMed
    1. Sjostrom L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014;311(22):2297–304. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources